Literature DB >> 18772644

Screening for primary aldosteronism in a cohort of Brazilian patients with resistant hypertension.

Armando R Nogueira1, Katia V Bloch.   

Abstract

The objective was to estimate the prevalence of plasma aldosterone concentration:plasma renin activity ratio >30 ng/dL:ng/mL/h in patients with resistant hypertension and to describe the computed tomography findings of adrenal glands in those with elevated ratios. In a cross-sectional design, 492 patients were enrolled. All patients with plasma aldosterone concentration:plasma renin activity ratio >or=30 ng/dL:ng/mL/h (n=77) underwent abdominal computed tomography. Patients with an adrenal image of possible aldosterone-producing adenoma underwent a saline-loading test. The prevalence of elevated plasma aldosterone concentration:plasma renin activity ratio was 15.7% (95% confidence interval, 12.6-19.2). Twelve patients showed adrenal abnormalities on computed tomography. The level of renin was low in 50% of the sample. Results indicate a low prevalence of aldosterone-producing adenoma. Our evidence points out the importance of confirming the hypothesis that essential hypertension, low-renin hypertension, and idiopathic hyperaldosteronism could be the same disease, but at different neurohormonal stages, and aldosterone-producing adenoma may be yet another disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772644      PMCID: PMC8109870          DOI: 10.1111/j.1751-7176.2008.08421.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  20 in total

1.  Potentially high prevalence of primary aldosteronism in a primary-care population.

Authors:  P O Lim; P Rodgers; K Cardale; A D Watson; T M MacDonald
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

2.  Prevalence and role of a raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice.

Authors:  Paul L Padfield
Journal:  Clin Endocrinol (Oxf)       Date:  2003-10       Impact factor: 3.478

3.  Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.

Authors:  Mari K Nishizaka; Monique Pratt-Ubunama; Mohammad A Zaman; Stacey Cofield; David A Calhoun
Journal:  Am J Hypertens       Date:  2005-06       Impact factor: 2.689

Review 4.  Mineralocorticoid hypertension.

Authors:  P M Stewart
Journal:  Lancet       Date:  1999-04-17       Impact factor: 79.321

Review 5.  The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism?

Authors:  Pitt O Lim; Allan D Struthers; Thomas M MacDonald
Journal:  J Hypertens       Date:  2002-01       Impact factor: 4.844

6.  Effect of spironolactone on blood pressure in subjects with resistant hypertension.

Authors:  Neil Chapman; Joanna Dobson; Sarah Wilson; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Journal:  Hypertension       Date:  2007-02-19       Impact factor: 10.190

7.  Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome.

Authors:  Fiemu E Nwariaku; Barbra S Miller; Richard Auchus; Shelby Holt; Lori Watumull; Bart Dolmatch; Shawna Nesbitt; Wanpen Vongpatanasin; Ronald Victor; Frank Wians; Edward Livingston; William H Snyder
Journal:  Arch Surg       Date:  2006-05

8.  Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing.

Authors:  Sue Hood; John Cannon; Roger Foo; Morris Brown
Journal:  Clin Med (Lond)       Date:  2005 Jan-Feb       Impact factor: 2.659

Review 9.  Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.

Authors:  Murray Epstein
Journal:  Am J Med       Date:  2006-11       Impact factor: 4.965

Review 10.  The current epidemic of primary aldosteronism: causes and consequences.

Authors:  Norman M Kaplan
Journal:  J Hypertens       Date:  2004-05       Impact factor: 4.844

View more
  3 in total

1.  Human aldosterone synthase gene polymorphism promotes miRNA binding and regulates gene expression.

Authors:  Shreekrishna Maharjan; Brahmaraju Mopidevi; Meenakshi Kaul Kaw; Nitin Puri; Ashok Kumar
Journal:  Physiol Genomics       Date:  2014-10-28       Impact factor: 3.107

2.  Resistant hypertension and undiagnosed primary hyperaldosteronism detected by use of a computerized database.

Authors:  Emmeline A Garcia; Julio R Lopez; Joy L Meier; Arthur L M Swislocki; David Siegel
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-03-28       Impact factor: 3.738

3.  Refractory Hypertension and Risks of Adverse Cardiovascular Events and Mortality in Patients With Resistant Hypertension: A Prospective Cohort Study.

Authors:  Claudia R L Cardoso; Gil F Salles
Journal:  J Am Heart Assoc       Date:  2020-08-27       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.